RoActemra (tocilizumab): Temporary supply shortage for 162 mg solution for subcutaneous injection and RoActemra 20 mg/mL concentrate for solution for infusion (IV) & recommendations to manage potential risk of disease flare in patient
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Direct healthcare professional communication (DHPC): RoActemra (tocilizumab) - Temporary Supply Shortage for 162 mg solution for subcutaneous injection (pre-filled syringe and pre-filled pen) and RoActemra 20mg/mL concentrate for solution for infusion(IV) (PDF/331.16 KB)
First published: 03/09/2021
Dissemination date: 03/09/2021
|Therapeutic area (MeSH)||
|Human ATC code||